Loading...
Please wait, while we are loading the content...
Similar Documents
Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM
| Content Provider | Scilit |
|---|---|
| Author | Wu, Xu Li, Yashan Li, Dexuan |
| Copyright Year | 2021 |
| Description | Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy |
| Abstract | Purpose: The pancreatic islet specific microRNA-375 (miR-375) is overexpressed in type 2 diabetes mellitus (T2DM) patients suppressing the glucose-induced insulin secretion. Thus, miR-375 may serve as a biomarker for the early prediction of T2DM among high-risk individuals. We conducted this clinical study to assess the significance of miR-375 among type 2 diabetes mellitus (T2DM) patients and their first-degree relatives. Patients and Methods: We included 56 Han Chinese individuals (N: NGT = 21, T2DM = 10, FD-NGT =13 and FD-T2DM = 12) who received medical health check-ups from January 2018 to September 2018 at The Third Hospital of Yunnan Province, China. They were categorized as normal glucose tolerance (NGT), T2DM, first-degree relatives with normal glucose tolerance (FD-NGT) and first-degree relatives with T2DM (FD-T2DM). OGTT, C-peptide and Insulin tests were performed to confirm the diagnosis. The miR-375 levels were determined by Quantitative real-time RT-PCR (qRT-PCR). Results: The OGTT test showed a significant difference in T2DM and FD-T2DM groups compared with NGT and FD-NGT (p< 0.05). Similar results were observed during C-peptide and insulin tests. Interestingly, the 2-hour insulin test showed FD-NGT group having a significantly higher mean ± standard error of (64.240 ± 12.775) compared to NGT (28.836 ± 10.875). Assessment of miR-375 expression levels in 4 groups showed a significant up-regulation in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A slight increase in miRNA expression was observed in FD-NGT compared with NGT group but was not statistically significant. Conclusion: The OGTT, C-peptide and insulin tests revealed a statistically significant difference in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A significantly higher miR-375 expression was also observed in T2DM and FD-T2DM groups compared with NGT and FD-NGT and thus, miR-375 may serve as a stable biomarker for the early prediction of T2DM among high-risk individuals. |
| Related Links | https://www.dovepress.com/getfile.php?fileID=68098 |
| Ending Page | 1451 |
| Page Count | 7 |
| Starting Page | 1445 |
| ISSN | 11787007 |
| DOI | 10.2147/dmso.s298735 |
| Journal | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy |
| Volume Number | ume 14 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2021-03-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Microrna-375 Type 2 Diabetes Mellitus |
| Content Type | Text |
| Subject | Internal Medicine Pharmacology |
